Similarly, Guan et al. [169] utilized extracellular vesicles (EVs) obtained from breast cancer cells to facilitate the targeted delivery of the exogenous p53 protein, which was modified with triphenylphosphine (TPP). This evidence concerns the gene TP53 and breast carcinoma.